Filing Details

Accession Number:
0001209191-14-027708
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-04-15 20:41:02
Reporting Period:
2014-04-15
Filing Date:
2014-04-15
Accepted Time:
2014-04-15 20:41:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1401914 Cerulean Pharma Inc. CERU Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
59478 Lilly Eli & Co Lilly Corporate Center
Indianapolis IN 46285
No No Yes No
1575852 Lilly Ventures Fund I Llc C/O Cerulean Pharma Inc.
Cambridge MA 02139
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-04-15 931,485 $0.00 931,485 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-04-15 299,213 $0.00 1,230,698 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-04-15 192,209 $0.00 1,422,907 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-04-15 199,875 $0.00 1,622,782 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-04-15 733,445 $7.00 2,356,227 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Convertible Preferred Stock Disposition 2014-04-15 13,513,513 $0.00 931,485 $0.00
Common Stock Series D Convertible Preferred Stock Disposition 2014-04-15 4,340,831 $0.00 299,213 $0.00
Common Stock 7% Convertible Promissory Notes Disposition 2014-04-15 0 $0.00 192,209 $7.00
Common Stock 7% Convertible Promissory Notes Disposition 2014-04-15 0 $0.00 199,875 $5.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. In connection with the completion of the Company's initial public offering, each share of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.0689-for-1 basis into the number of shares of Common Stock listed in Table I, column 5 and Table II, column 7 without payment of further consideration. Neither the Series C Convertible Preferred Stock nor the Series D Convertible Preferred Stock had an expiration date.
  2. These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund.
  3. Represents the number of shares of Common Stock issued upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on August 13, 2013 through April 15, 2014, at a conversion price of $7.00 per share of Common Stock, which was the initial public offering price. The Notes had no expiration date and were exercisable any time after August 15, 2014 at the holder's election or automatically upon a qualified financing.
  4. Represents the number of shares of Common Stock issuable upon conversion of all principal and accrued interest on the 7% Convertible Promissory Notes issued on February 18, 2014 through April 15, 2014, at a conversion price equal to $5.43 per share of Common Stock, which was equal to 77.5% of the Company's initial public offering price. The Notes had no expiration date and were exercisable any time after February 26, 2015 at the holder's election or automatically upon a qualified financing.